|
|
Providence Oregon is pleased that union-represented RNs at all eight Oregon hospitals voted to approve new contracts and end their strikes.
Providence’s Oregon bargaining teams have reached tentative agreements with nurses at all eight Providence hospitals in Oregon.
Gary tells his story about the difficult journey back to the slopes of Mt. Hood after receiving life-saving surgery for pancreatic cancer.
Feb. 5, 2025 News Release: Providence Medical Group Announces Tentative Agreement with Hospitalists, Palliative Care Physicians at Providence St. Vincent
This is an exciting new trial comparing robotic assisted laparoscopy to open hysterectomy and lymph node assessment for the treatment of early-stage cervical cancer.
Jan. 29, 2025 News Release: Joint statement on mediation between Providence and Oregon Nurses Association
Jan. 11, 2025 News Release: With record numbers of caregivers returning to work, our ministries are now in a position to discuss resuming mediated negotiation sessions.
Here’s what you need to know about getting care at Providence hospitals and clinic during the Oregon Nurses Association strikes that start Friday, January 10.
Jan. 8, 2025 News Release: We have negotiated in good faith to reach agreements with Oregon Nurses Association (ONA), but these strikes will compromise access to care
Jan. 7, 2025 News Release: Providence informs state leaders the open-ended strike planned by leaders of the Oregon Nurses Association puts health care access at “significant risk” in the state.
Dec. 30, 2024 News Release: Providence is given notice by ONA to strike at multiple Oregon ministries, including our eight acute hospitals
Catch the 2024 highlights from Providence Cancer Institute in this year-end recap focused on research advancements, caregiver recognition and community engagement.
Discover how Dean Lookingbill’s battle with lymphoma led him to CAR T-cell therapy at Providence Cancer Institute.
Two global studies open at Providence Cancer Institute will evaluate combinations of medications to help stop or slow the growth of cancer in solid tumors.
Real-world data from Providence, Illumina and Microsoft Research finds cancer patients with early genomic testing received better precision treatment, underlines urgency to become standard practice
R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.
The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.
New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.
Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.
Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.